New Dengue Vaccine Could Protect People From Disease If Targeted Accurately
Thomson Reuters Foundation: Dengue vaccine no silver bullet but worth a shot for those who need it most
Stefan Flasche, assistant professor at the London School of Hygiene & Tropical Medicine’s department of infectious disease epidemiology
“…A new London School of Hygiene & Tropical Medicine-led study published in the journal PLOS Medicine, initiated by the World Health Organization, and conducted with a team of international experts … showed that giving [the CYD-TDV dengue vaccine] only to those populations with a high burden of disease has the potential to prevent about one out of five dengue hospitalizations. It predicts that a substantial positive impact of vaccination can be achieved if targeted at individuals who most likely had an infection before and, if priced competitively, a cost-effectiveness profile that is similar to that of other vaccines currently in use. … The global health community must ensure that we are in a position to make best use of this dengue vaccine until other, more effective means of prevention become available. CYD-TDV is no silver bullet, but if targeted accurately it will bring help to those who need it most” (11/29).